Trademark Overview
On Wednesday, May 18, 2022, a trademark application was filed for LUMVYTA with the United States Patent and Trademark Office. The USPTO has given the LUMVYTA trademark a serial number of 97417578. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Saturday, June 24, 2023. This trademark is owned by Day One Biopharmaceuticals, Inc.. The LUMVYTA trademark is filed in the Pharmaceutical Products and Medical & Beauty Services & Agricultural Services categories with the following description:
Pharmaceutical preparations; pharmaceutical preparations for human use; pharmaceutical preparation for the prevention and treatment of cancer; pharmaceutical preparations for the treatment of oncological diseases; pharmaceutical preparations and substances for the prevention and treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; targeted medical preparations for use in the field of cancer prevention and treatment; medical and veterinary preparations for the delivery of compounds to the body for the treatment and prevention of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatolog...
Medical information services; healthcare services; research, development, and evaluation of pharmaceutical preparations for the prevention and treatment of cancer; laboratory analysis and research of drugs and pharmaceutical products; research and development services in the fields of oncology, immunotherapy, chemotherapy, and combination therapies for the treatment of cancer and tumors; providing medical research information in the fields of oncology, immunotherapy, chemotherapy and combination therapies; scientific advisory services, namely, providing scientific information, advice, and consultancy in the field of cancer treatment; healthcare services, namely, providing cancer treatment information to physicians, health care professionals, and patients; design, development, research, and testing of drugs and pharmaceuticals for the treatment and/or prevention of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncologic...
